ARTICLE | Company News

Guerbet, Sirtex Medical deal

March 31, 2014 7:00 AM UTC

The companies partnered to develop Sirtex's SIR-Spheres microspheres and Guerbet's Lipiodol ethiodized oil to be used in combination or in sequence to treat inoperable primary and secondary liver cancers. The first project under the deal will comprise a series of clinical trials to evaluate the potential for synergism between the two therapies, and whether they can be combined or sequenced to deliver optimized tumor control. The partners could not be reached in time for publication. ...